Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "Cytotoxic chemotherapy"
Filter
Filter
Article category
Publication year
Case Report
A Case of Hepatocellular Carcinoma with Pulmonary Metastasis Who Showed Complete Response by Cytotoxic Chemotherapy after Sorafenib Failure
Hwa-Sun Park, Jae Young Jang, Min Young Baek, Yong Kwon Kim, Hyun Jin Youn, Su Young Back, Soung Won Jeong, Sae Hwan Lee, Sang Gyune Kim, Sang Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim
J Liver Cancer. 2017;17(1):72-76.   Published online March 31, 2017
DOI: https://doi.org/10.17998/jlc.17.1.72
  • 2,224 Views
  • 26 Downloads
AbstractAbstract PDF
Hepatocellular carcinoma (HCC) is the 2nd most common cause of cancer related death in Korea and well-known malignancy with poor prognosis. Sorafenib is the first-line molecular targeted agent in patients with extra-hepatic spread of HCC. However, complete response is extremely rare in patients treated with sorafenib and the disease control rate is only 43%. We report a 53-year-old man with advanced HCC with pulmonary metastasis who showed complete response by cytotoxic chemotherapy with doxorubicin and cisplatin with relatively tolerable adverse effects after failure of treatment with sorafenib.
Close layer
Review Article
Systemic Cytotoxic Therapy in Advanced HCC
Seung Tae Kim, Yeul Hong Kim
Journal of the Korean Liver Cancer Study Group. 2013;13(1):18-21.   Published online February 28, 2013
DOI: https://doi.org/10.17998/jlc.13.1.18
  • 1,236 Views
  • 6 Downloads
AbstractAbstract PDF
Hepatocellular carcinoma (HCC) is an aggressive tumor that occurs in chronic liver disease and cirrhosis. Surgical therapy including transplantation or local ablation may offer the prospect of cure. However, most patients were diagnosed with unresectable, advanced disease. For these patients, providing liver function and performance status permit, systemic therapies are often used with palliative intent. Although recently molecular targeted therapies have been employed with some success, cytotoxic chemotherapy had been used in general. Efficacy with conventional cytotoxic chemotherapy is modest at best, and the duration of benefit is limited. Although few randomized trials have been conducted, no single regimen has emerged as superior to any other, and no drug or regimen has been unequivovally shown to improve survival.
Close layer

JLC : Journal of Liver Cancer